A small clinical trial has provided the first evidence that the psychedelic medicine psilocybin may have a role to play in the treatment of anorexia nervosa, an eating dis
The psychedelic compound in magic mushrooms – psilocybin – can improve the symptoms of severe depression, according to the largest randomised, controlled trial of the therapy carried out to
Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was effective in a phase 2b trial, although shares in the
The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly.
Compass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy firm Mind Medicine is aiming to follow suit by up-listing its shares on
UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic m
AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo